Nexalin Technology (NXL) EBIT Margin (2021 - 2026)
Nexalin Technology's (NXL) quarterly EBIT Margin came in at 14179.95% in Q1 2026, down 927631.0% year-on-year from N/an in Q1 2025, and down 910.07% quarter-over-quarter from 1403.86% in Q4 2025.
Nexalin Technology (NXL) EBIT Margin (2021 - 2026) Analysis & Trends
Nexalin Technology's EBIT Margin history runs 6 years deep, the most recent figure standing at 14179.95% for Q1 2026.
- On a quarterly basis, EBIT Margin fell 927631.0% year-over-year to 14179.95% in Q1 2026; TTM through Mar 2026 was 3084.22%, a 354772.0% increase from a year earlier, with the FY2025 full-year figure at 2781.69%, up 181445.0% from the prior year.
- EBIT Margin declined to 14179.95% in Q1 2026 per NXL's latest filing, from 1403.86% in the prior quarter.
- Across five years, EBIT Margin topped out at 53.77% in Q3 2022 and bottomed at 14179.95% in Q1 2026.
- The 5-year median for EBIT Margin is 2550.48% (2023), against an average of 4973.09%.
- Across the five-year window, EBIT Margin plunged 996381 bps in 2023 and soared 917562 bps in 2025, its largest moves.
- Year by year, EBIT Margin stood at 1872.83% in 2022, then slumped by 322 bps to 7910.37% in 2023, then plunged by 34 bps to 10579.48% in 2024, then jumped by 87 bps to 1403.86% in 2025, then tumbled by 910 bps to 14179.95% in 2026.
- Per Business Quant, the three latest NXL EBIT Margin figures stand at 14179.95% (Q1 2026), 1403.86% (Q4 2025), and 12924.3% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 12.05% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 15.55% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 19.10% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 21.16% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 28.97% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 21.42% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 6.17% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 10.04% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Nexalin Technology | 9.32 Mn | 6.61 Mn | 13,133.00 | -14,179.95% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14,179.95% |
| Dec 31, 2025 | -1,403.86% |
| Sep 30, 2025 | -12,924.30% |
| Jun 30, 2025 | -2,296.22% |
| Mar 31, 2025 | -4,903.63% |
| Dec 31, 2024 | -10,579.48% |
| Sep 30, 2024 | -6,962.11% |
| Jun 30, 2024 | -4,832.42% |
| Mar 31, 2024 | -1,364.81% |
| Dec 31, 2023 | -7,910.37% |
| Sep 30, 2023 | -10,017.57% |
| Jun 30, 2023 | -2,467.25% |
| Mar 31, 2023 | -2,550.48% |
| Dec 31, 2022 | -1,872.83% |
| Sep 30, 2022 | -53.77% |
| Jun 30, 2022 | -107.44% |
| Mar 31, 2022 | -116.02% |
| Dec 31, 2021 | -2,406.30% |
| Sep 30, 2021 | -3,207.88% |